Your testosterone levels are borderline and require confirmatory testing with a repeat early morning measurement before making any diagnosis.
With a total testosterone of 392 ng/dL and free testosterone of 2.7 pg/mL, you fall into a diagnostic gray zone that mandates careful evaluation before any treatment decisions.
Interpretation of Your Values
Your total testosterone of 392 ng/dL sits above the diagnostic threshold of 300 ng/dL used by the AUA guideline 1, but your free testosterone of 2.7 pg/mL is markedly low—well below the 2.5th percentile of 66 pg/mL (and far below the lower limit of 120 pg/mL for men aged 19-39 years) established by standardized equilibrium dialysis methods 2.
This discordance between total and free testosterone is clinically significant. The free testosterone level suggests genuine androgen deficiency despite a seemingly "normal" total testosterone. Research demonstrates that men with total testosterone between 250-400 ng/dL frequently have low free testosterone, and total testosterone must exceed 350-400 ng/dL to reliably predict normal free testosterone 3. Your free testosterone is so profoundly low (2.7 pg/mL versus reference range starting at 66 pg/mL) that it represents severe biochemical hypogonadism regardless of your total testosterone level.
Required Next Steps
1. Confirm the Diagnosis
- Obtain a second early morning (7-11 AM) fasting blood draw measuring both total testosterone and free testosterone 1. This is mandatory—30% of men with initially low testosterone have normal levels on repeat testing 4.
- Use the same laboratory and methodology for consistency 1.
- Ensure you are fasting, as glucose and food intake suppress testosterone 4.
2. Measure LH and FSH
- Check serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to determine if this is primary (testicular) or secondary (pituitary/hypothalamic) hypogonadism 1.
- Low/normal LH with low testosterone indicates secondary hypogonadism.
- Elevated LH/FSH indicates primary testicular failure.
3. Assess for Conditions Affecting SHBG
Your discordant total versus free testosterone suggests altered sex hormone-binding globulin (SHBG) levels. Check for:
- Obesity (calculate BMI)—obesity lowers SHBG and can cause falsely reassuring total testosterone while free testosterone remains low 4, 5
- Diabetes or metabolic syndrome
- Liver disease
- Thyroid dysfunction
- Medications (opioids, corticosteroids) 1
4. Document Symptoms and Signs
The diagnosis requires both low testosterone levels and clinical manifestations 1. Specifically assess for:
Symptoms:
- Reduced libido and sexual activity
- Erectile dysfunction
- Decreased energy, endurance, work performance
- Fatigue
- Depression, irritability, poor concentration
- Infertility
Physical signs:
- Testicular size and consistency
- Body hair distribution
- Gynecomastia
- Body composition (increased fat, decreased muscle)
- Bone density loss history
Critical Clinical Pitfall
Do not rely solely on total testosterone in your case. With free testosterone at 2.7 pg/mL—representing less than 5% of the lower normal limit—you have severe biochemical androgen deficiency that total testosterone alone fails to capture 3, 6. This is precisely the scenario where free testosterone measurement is essential 4. Men with elevated SHBG can have normal or even high total testosterone while suffering from primary hypogonadism due to profoundly low free testosterone 6.
Treatment Consideration
If repeat testing confirms low free testosterone (<66 pg/mL) with symptoms/signs, you meet criteria for testosterone deficiency and are a candidate for testosterone therapy 1. The profoundly low free testosterone (2.7 pg/mL) in your case is more clinically relevant than the borderline total testosterone, as free testosterone better reflects bioavailable androgen exposure and correlates more strongly with hypogonadal symptoms 7, 6.
However, do not initiate therapy until confirmatory testing is complete and the etiology (primary vs. secondary) is established through LH/FSH measurement 1. If LH is low/normal, you may be a candidate for selective estrogen receptor modulators rather than exogenous testosterone, particularly if fertility preservation is desired 1.